Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

Autor: Florian Heil, Galina Babitzki, Alice Julien-Laferriere, Chia-Huey Ooi, Manuel Hidalgo, Christophe Massard, Maria Martinez-Garcia, Christophe Le Tourneau, Mark Kockx, Peter Gerber, Simona Rossomanno, Oliver Krieter, Angelika Lahr, Norbert Wild, Suzana Vega Harring, Katharina Lechner

Publikováno v: Translational Oncology, Vol 14, Iss 2, Pp 100984- (2021)

Vanucizumab is a novel bispecific antibody inhibiting vascular endothelial growth factor (VEGF-A) and angiopoietin-2 (Ang-2) that demonstrated safety and anti-tumor activity in part I of a phase I study of 42 patients with advanced solid tumors. Part

Externí odkaz: https://doaj.org/article/ed93c95472434a2ab2071afec0adca67

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model

Autor: Hans-Joachim Schmoll, Thomas Mueller, Henrike Lucas, Juana Freystein

Publikováno v: Molecules
Volume 24
Issue 16
Molecules, Vol 24, Iss 16, p 2865 (2019)

Vascular endothelial growth factor (VEGF) inhibition by the addition of bevacizumab to the chemotherapy regimen of metastatic colorectal cancer leads to an improved outcome. However, anti-angiogenic tumor therapy targeting a single factor may be limi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96aab6d9f1b2d9b62418ec81b1d4a806

Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment

Autor: Jeremie Guedj, Marion Kerioui, Francois Mercier, Rene Bruno, Oliver Krieter, Solène Desmée

Publikováno v: Journal of Pharmacokinetics and Pharmacodynamics
Journal of Pharmacokinetics and Pharmacodynamics, Springer Verlag, 2020, 47 (6), pp.613-625. ⟨10.1007/s10928-020-09714-z⟩

The purpose of this work is to assess the heterogeneity across organs of response to treatment in metastatic colorectal patient based on longitudinal individual target lesion diameters (ILD) in comparison to sum of tumor lesion diameters (SLD). Data

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::698bc83a882672fcdc183b5a0540fe14
https://pubmed.ncbi.nlm.nih.gov/32865652

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

Autor: Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López López, Carlos, García Alfonso, Pilar, Hussein, Maen, Limon Miron, Maria Luisa, Cervantes, Andrés, Montagut Viladot, Clara, Santos, Cristina, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert, McCAVE Study Group

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
The Oncologist
ONCOLOGIST
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

Background Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b417cab815b95000410f7e209373914
http://hdl.handle.net/2445/174671